Results 231 to 240 of about 73,620 (322)

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms

open access: yesBritish Journal of Haematology, EarlyView.
In our central morphological review system, megakaryocyte counts are prioritized alongside BM cellularity to differentiate between AA and MDS. A retrospective analysis of patients with SAA and those with LR‐hMDS, registered in that system, revealed a significant difference in outcomes.
Tomoya Maeda   +25 more
wiley   +1 more source

Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression

open access: yesBritish Journal of Haematology, EarlyView.
Multiple myeloma (MM) with chromosome 1q21 gain/amplification (1q+) has been reported to respond poorly to daratumumab, a human monoclonal antibody targeting CD38. Our findings revealed significantly lower CD38 expression in patients with 1q+ MM than in those with 1q wild type (WT) MM.
Wataru Kuroki   +9 more
wiley   +1 more source

STAB1 Promotes Acute Myeloid Leukemia Progression by Activating the IKK/NF‐κB Pathway and Increasing M2 Macrophage Polarization

open access: yesCancer Science, EarlyView.
In this study, we explored the effects of silenced STAB1 expression in AML cells on the polarization of M2‐like macrophages, as well as the involvement of nuclear factor‐kappa B (NF‐κB) signaling pathways in the pro‐oncogenic roles of STAB1. By investigating the expression pattern of STAB1 along with its regulatory mechanisms in AML patients, we aimed ...
Jiaxiu Yin   +4 more
wiley   +1 more source

P592: Cytogenetic and microarray analysis of prenatally detected congenital heart defects (CHD): Diagnostic findings and variation among CHD subtypes

open access: yesGenetics in Medicine Open
Stuart Schwartz   +7 more
doaj  

Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor‐Insensitive Breast Cancer Cells

open access: yesCancer Science, EarlyView.
Pimitespib, an HSP90 inhibitor, enhances the antitumor activity of PARP inhibitors by impairing the homologous recombination (HR) repair pathway in PARP inhibitor‐insensitive breast cancer cells. This is achieved by promoting the downregulation of proteins involved in HR, such as BRCA1, BRCA2, and RAD51.
Hiromi Muraoka   +4 more
wiley   +1 more source

Cytogenetic Studies in Lower Vertebrates. I

open access: bronze, 1966
Yoshio Ojima   +2 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy